Danaher to acquire Abcam

Headline: Danaher to acquire Abcam

Date: 28/08/2023

Type: Acquisition

Acquiror: Danaher Corporation

Target: Abcam plc

Target Services: Life science research tools

Valuation: $24.00 per share

Country: United Kingdom

Continent: Europe

Target Industry: Life Sciences

Rationale: Abcam’s extensive expertise in the supply of highly validated antibodies, reagents, biomarkers, and assays offers a synergistic alignment with Danaher’s existing capabilities.

Summary: Danaher Corporation announces the acquisition of Abcam plc for $24.00 per share in cash, enhancing its presence in life sciences and supporting its strategy to accelerate drug discovery through innovative research tools.

Company Insight provides expert company research services. If you are looking for company research or market analysis services please get in touch